Equities

Akebia Therapeutics Inc

Akebia Therapeutics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)1.94
  • Today's Change0.075 / 4.02%
  • Shares traded2.77m
  • 1 Year change+102.08%
  • Beta0.6721
Data delayed at least 15 minutes, as of Nov 08 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments4390150
Total Receivables, Net394052
Total Inventory162237
Prepaid expenses203333
Other current assets, total------
Total current assets118185271
Property, plant & equipment, net163441
Goodwill, net595959
Intangibles, net3672108
Long term investments------
Note receivable - long term------
Other long term assets115.3748
Total assets242356529
LIABILITIES
Accounts payable151834
Accrued expenses6876109
Notes payable/short-term debt000
Current portion long-term debt/capital leases183298
Other current liabilities, total03.7421
Total current liabilities100130261
Total long term debt17340
Total debt356698
Deferred income tax------
Minority interest------
Other liabilities, total155187194
Total liabilities272351455
SHAREHOLDERS EQUITY
Common stock0.000.000.00
Additional paid-in capital1,5781,5621,537
Retained earnings (accumulated deficit)(1609)(1557)(1463)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total0.010.010.01
Total equity(31)5.2374
Total liabilities & shareholders' equity242356529
Total common shares outstanding195184177
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.